NCT02154737View on ClinicalTrials.gov

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 3, 2020

Study Completion Date

September 3, 2020

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.

DRUG

Erlotinib

Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Tony Reid, M.D., Ph.D.

OTHER

NCT02154737 - Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter